Colorectal cancer prevention and treatment

[1] Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen [J]. ANNALS OF ONCOLOGY, 1998, 9 (11) : 1251 - 1253

[2] 5-ETHYNYLURACIL (776C85) - A POTENT MODULATOR OF THE PHARMACOKINETICS AND ANTITUMOR EFFICACY OF 5-FLUOROURACIL [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) : 11064 - 11068

[3] Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3085 - 3096

[4] Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin [J]. GASTROENTEROLOGY, 1998, 114 (05) : 873 - 877

[5] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744

[6] Bleiberg H, 1998, SEMIN ONCOL, V25, P32

[7] BOLAND CR, 1998, GENETIC BASIS HUMAN, P333

[8] BOLAND CR, 1999, TXB GASTROENTEROLOGY, P2023

[9] RANDOMIZED COMPARISON OF 2 SCHEDULES OF FLUOROURACIL AND LEUCOVORIN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 14 - 20

[10] Buyse M, 1996, J NATL CANCER I, V88, P252

[1] Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen [J]. ANNALS OF ONCOLOGY, 1998, 9 (11) : 1251 - 1253

[2] 5-ETHYNYLURACIL (776C85) - A POTENT MODULATOR OF THE PHARMACOKINETICS AND ANTITUMOR EFFICACY OF 5-FLUOROURACIL [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) : 11064 - 11068

[3] Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3085 - 3096

[4] Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin [J]. GASTROENTEROLOGY, 1998, 114 (05) : 873 - 877

[5] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744

[6] Bleiberg H, 1998, SEMIN ONCOL, V25, P32

[7] BOLAND CR, 1998, GENETIC BASIS HUMAN, P333

[8] BOLAND CR, 1999, TXB GASTROENTEROLOGY, P2023

[9] RANDOMIZED COMPARISON OF 2 SCHEDULES OF FLUOROURACIL AND LEUCOVORIN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 14 - 20

[10] Buyse M, 1996, J NATL CANCER I, V88, P252